Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
2011

Relapse Rates in Schizophrenia: Monotherapy vs. Polypharmacy

Sample size: 183 publication 10 minutes Evidence: moderate

Author Information

Author(s): Millier Aurelie, Sarlon Emmanuelle, Azorin Jean-Michel, Boyer Laurent, Aballea Samuel, Auquier Pascal, Toumi Mondher

Primary Institution: Creativ-Ceutical France

Hypothesis

Does the type of antipsychotic treatment (monotherapy vs. polypharmacy) affect the rate of relapse in schizophrenic patients over a 2-year period?

Conclusion

Antipsychotic polypharmacy is not statistically associated with an increase in relapse after adjusting for propensity scores.

Supporting Evidence

  • 50 patients (27.3%) had at least one period of relapse.
  • Patients receiving polypharmacy had a higher general psychopathology PANSS subscore.
  • Relapse was found in 23.7% of patients given monotherapy and 33.3% given polypharmacy.

Takeaway

This study looked at whether taking one or more antipsychotic medications affects relapse in people with schizophrenia. It found that taking multiple medications didn't lead to more relapses.

Methodology

A multicenter cohort study with a propensity-adjusted analysis over a 2-year period.

Potential Biases

Potential confounding factors due to non-random assignment of treatment.

Limitations

The treatment was not randomly assigned, which may confound results; the sample may not be representative of all schizophrenic patients.

Participant Demographics

70.9% male, mean age 24.8 years.

Statistical Information

P-Value

p = 0.16

Confidence Interval

HR = 1.686 (0.812; 2.505)

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-244X-11-24

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication